Vasant "Vas" Narasimhan (born August 26, 1976) is an American physician and the chief executive officer of Novartis. [1] [2] [3] [4] He succeeded Joseph Jimenez who left Novartis in 2018. [5]

Jan 31, 2024 · Since becoming CEO of Novartis in 2018, Vas has led a strategic and cultural transformation to build a fully focused medicines company—one that delivers high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

Mar 18, 2020 · When Vas Narasimhan was told he was being considered for the top job at Swiss drugs giant Novartis, he thought there had been a mistake.

Vasant “Vas” Narasimhan is an American physician of Indian origin who was named the Chief Executive Officer (CEO) of Novartis International AG, a Swiss multinational pharmaceutical company, in September 2017. He is expected to replace Joseph Jimenez, the incumbent CEO, in …

Apr 12, 2024 · Over the past seven years, Vasant ‘Vas’ Narasimhan has led the transformation of Novartis into a focussed medicines company rebuilt on the bedrock of R&D and innovation.

Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the company's business operations.

Since becoming CEO of Novartis in 2018, Vas has led a strategic and cultural transformation to build a fully focused medicines company—one that delivers high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D …

Jan 31, 2025 · Kisqali is undergoing “a very rapid launch” in early breast cancer, Novartis CEO Vas Narasimhan said during a media call Friday. As Narasimhan shared during the J.P. Morgan Healthcare ...

Feb 4, 2022 · Before capturing the top job at Novartis in 2018, Vas Narasimhan had already left his mark on the Swiss drugmaker’s headquarters.